14Oct
09Sep
Local Biotech Firm Develops Drug For Respiratory Distress In COVID-19 Patients
Pittsburgh-based biotech company CytoAgents is launching into phase one of clinical trials this month on a drug designed to treat people with COVID-19 who develop serious respiratory distress when their immune system overreacts to the virus. Read more >>
08Jul
Pittsburgh biotech company wins funding for Covid-19 drug
Pittsburgh biotech company CytoAgents has received $250,000 from the Richard King Mellon Foundation to help develop its drug candidate to treat cytokine storm, a deadly complication of Covid-19 and other upper respiratory illnesses. CytoAgents has been working on phase I and phase II clinical trials for GP1681, its existing drug candidate that even before Covid-19 had treated the immune response that causes inflammation and respiratory distress for people with severe influenza. It received a $1.6 million grant from the National...
14May
CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm
CytoAgents awarded $1.6 million National Institutes of Health (NIH) grant to accelerate treatment for cytokine storm. Read more >>
30Apr
Pittsburgh biotech firm involved in development of potential COVID-19 treatment
CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment. Read more >>
30Apr